Less than 10% of individuals eligible to benefit from GLP-1 drugs like Wegovy can access them, states the World Health Organization as it issues its initial advice on the therapies.
Given in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for more widespread and fairer availability to GLP-1 medication.
Based on projections, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"Our latest guidelines affirms that obesity is a chronic disease that can be managed with thorough and ongoing care," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are major obstacles to broad availability to the jabs that can aid individuals in losing substantial weight, explains the organization.
Skinny Jab Scarcity
Even in the current most favorable scenario, the manufacturing of these medications would only suffice for approximately 100 million people – less than 10% of the global need, according to the health organization.
The guideline calls on countries and companies to increase availability, through approaches like voluntary licensing.
Exclusive production rights on semaglutide – the core ingredient of a leading brand – is set to lapse in a number of countries in 2026.
How Obesity Drugs Operate
GLP-1 drugs replicate a body's own hormone to delay gastric emptying, suppress the appetite and enhance feelings of fullness so users reduce food intake.
People typically see weight reduction within a few weeks of beginning the regular doses.
Studies indicates patients may put most of the weight back on within a year of stopping the drug, because their usual hunger resume.
Being above a healthy weight increases your chance for contracting diseases, like type 2 diabetes, heart disease, brain attack, and some malignancies.
Obesity impacts people in countries worldwide and was associated with over three and a half million fatalities worldwide in 2024, as per the WHO.
